Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke

IMPORTANCE: After the publication of the CHANCE (Clopidogrel in High Risk Patients With Acute Nondisabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke) clinical trials, the American Heart Association/American Stroke Assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xian, Ying, Xu, Haolin, Matsouaka, Roland, Laskowitz, Daniel T., Maisch, Lesley, Hannah, Deidre, Smith, Eric E., Fonarow, Gregg C., Bhatt, Deepak L., Schwamm, Lee H., Mac Grory, Brian, Feng, Wuwei, Fosbøl, Emil Loldrup, Peterson, Eric D., Johnson, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335137/
https://www.ncbi.nlm.nih.gov/pubmed/35900761
http://dx.doi.org/10.1001/jamanetworkopen.2022.24157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335137/
https://www.ncbi.nlm.nih.gov/pubmed/35900761
http://dx.doi.org/10.1001/jamanetworkopen.2022.24157

Ejemplares similares